Capstone Partners served as financial advisor to DCN Dx in connection with a growth equity investment from Martis Capital.
DCN Dx is a leading provider of contract development services for clients seeking to explore, develop and commercialize rapid diagnostic tests related to lateral flow assays.
DCN Dx supports an array of customers including global diagnostics manufacturers, non-profits seeking tests for low-resource settings and start-ups launching diagnostic-based products.
Over the past 15 years, DCN Dx has successfully developed more than 100 rapid diagnostic tests for its customers.
Martis Capital is a private equity firm which manages more than $1.2 billion of equity and is focused exclusively on investing in middle market growth companies in the healthcare industry.
